Receptor-independent induction of apoptosis by synthetic retinoids

Journal of Biological Regulators and Homeostatic Agents

Volumn 17, Issue 1, 2003, Pages 13-28

  Lotan, Reuben ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; CD437; Death receptors; Mitochondria; Retinoids

Indexed keywords

6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ADAPALENE; CASPASE; CD 2325; CELL NUCLEUS RECEPTOR; DNA; MITOGEN ACTIVATED PROTEIN KINASE; MM 002; MM 11453; MX 3350; MYC PROTEIN; PROTEIN BCL 2; PROTEIN P53; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; RETINOIC ACID RECEPTOR GAMMA; RETINOID; RETINOID DERIVATIVE; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BIOCHEMISTRY; CANCER CELL CULTURE; CELL DEATH; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRUCTURE; CONTROLLED STUDY; DNA DAMAGE; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN FUNCTION; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 0038147091     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (140)

1. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997; 278: 1073-7.
2. Lotan R. Retinoids and chemoprevention of aerodigestive tract cancer. Cancer Metastasis Rev 1997; 16: 349-56.
3. Lippman SM, Lotan R. Advances in the development of retinoids as chemopreventive agents. J Nutr 2000; 130 (Suppl.): S479-82.
4. Niles RM. Recent advances in the use of vitamin A (retinoids) in the prevention and treatment of cancer. Nutrition 2000; 16: 1084-90.
5. Dragnev KH, Rigas JR, Dmitrovsky E. The retinoids and cancer prevention mechanism. Oncologist 2000; 5: 361-8.
6. Chambon P. A decade of molecular biology of retinoic acid receptors. FASEB J 1996; 10: 940-54.
7. Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nature Rev Cancer 2001; 1: 181-93.
8. Xu X, Lotan R. Aberrant expression and function of nuclear retinoid receptors in cancer In: Nau H, Blaner ES, eds. The biochemical and molecular basis of vitamin A and retinoid action. Handbook of experimental pharmacology, vol. 139. Berlin: Springer Verlag, 1999; 323-43.
9. Sun SY, Lotan R. Retinois and their receptors in cancer development and chemoprevention. Crit Rev Oncol /Hematol 2002; 41: 41-55.
10. Muindi J, Frankel SR, Miller WH Jr, et al. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid "resistance" in patients with acute promyelocytic leukemia. Blood 1992; 79: 299-303.
11. Hong WK, Itri LM. Retinoids and human cancer. In: Sporn MB, Roberts AB, Goodman DS, eds. The retinoids. New York: Raven Press, 1994; 597-658.
12. Collins MD, Bao GE. Teratology of retinoids. Annu Rev Pharmacol Toxicol 1999; 39: 399-430.
13. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase II intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small cell lung cancer. J Natl Cancer Inst 2001; 93: 605-18.
14. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002; 16: 1940-58.
15. Nagpal S, Chandraratna RA. Recent developments in receptor selective retinoids. Curr Pharm Des 2000; 6: 919-31.
16. Dawson MI, Zhang X, Hobbs PD, Jong L. Synthetic retinoids and their usefulness in biology and medicine. In: Livera MA, ed. Vitamin A and retinoids: an update of biological aspects and clinical applications. Basel: Birkhauser Verlag, 2000: 161-96.
17. Sun SY, Yue P, Dawson MI, et al. Differential effects of synthetic nuclear retinoid receptor-selective retinoids on the growth of human non-small cell lung carcinoma cells. Cancer Res 1997; 57: 4931-9.
18. Sun SY, Yue P, Mao L, et al. Identification of receptor-selective retinoids that are potent inhibitors of the growth of human head and neck squamous cell carcinoma cells. Clin Cancer Res 2000; 6: 1563-73.
19. Lu X-P, Fanjul A, Picard N, et al. Novel retinoid-related molecules as apoptosis inducers and effective inhibitors of human lung cancer cells in vivo. Nature Med 1997; 3: 686-90.
20. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002; 16: 463-72.
21. Zhang XK. Vitamin A and apoptosis in prostate cancer. Endocr Relat Cancer 2002; 9: 87-102.
22. Nagy L, Thomazy VA, Heyman RA, Davies PJ. Retinoid-induced apoptosis in normal and neoplastic tissues. Cell Death Differ 1998; 5: 11-9.
23. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nat Med 2001; 7: 680-6.
24. Steller H. Mechanisms and genes of cellular suicide. Science 1995; 267: 1445-9.
25. Metcalfe A, Streuli C. Epithelial apoptosis. BioEssays 1997; 19: 711-20.
26. Green DR. Apoptotic pathways: the roads to ruin. Cell 1998; 94: 695-8.
27. Hengartner MO. The Biochemistry of apoptosis. Nature 2000; 407: 770-6.
28. Thomberry NA, Lazebnik Y. Caspase: enemies within. Science 1998; 281: 1312-6.
29. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol 1999; 11: 255-60.
30. Utz PJ, Anderson P. Life and death decision: regulation of apoptosis by proteolysis of signaling molecules. Cell Death Diff 2000; 7: 589-602.
31. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281: 1305-8.
32. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther 2001; 92: 57-70.
33. Belzacq AS, El Hamel C, Vieira HL, et al. Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by Ionidamine, arsenite and CD437. Oncogene 2001; 20: 7579-87.
34. Kroemer G, Zamzami N, Susin SA. Mitochondrial control of apoptosis. Immunol Today 1997; 18: 44-51.
35. Kuwana T, Mackey MR, Perkins G, et al. Bid, Bax, and lipids cooperate to form supramolecular openings in the outer mitochondrial membrane. Cell 2002; 111: 331-42.
36. Luo X, Budihardjo I, Zou H, et al. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94: 481-90.
37. Li H, Zhu H, Xu CJ, et al. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94: 491-501.
38. Eskes R, Desagher S, Antonsson B, et al. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol Cell Biol 2000; 20: 929-35.
39. Testa JR, Bellacosa A. AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 10983-5.
40. Bharti AC, Aggarwal BB. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 2002; 64: 883-8.
41. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995; 87: 1655-7.
42. Hsu CA, Rishi AK, Su-Li X, et al. Retinoid induced apoptosis through a retinoic acid nuclear receptor independent pathway. Blood 1997; 89: 4470-9.
43. Gianni M, de The H. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies. Leukemia 1999; 13: 739-49.
44. Mologni L, Ponzanelli I, Bresciani F, et al. The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 1999; 93: 1045-61.
45. Hail N Jr, Lotan R. Synthetic retinoid CD437 promotes rapid apoptosis in malignant human epidermal keratinocytes and G1 arrest in their normal counterparts. J Cell Physiol 2001; 186: 24-34.
46. Sun SY, Yue P, Chen X, Hong WK, Lotan R. The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res 2002; 62: 2430-6.
47. Wanner R, Henseleit-Walter U, Wittig B, Kolde G. Proliferation-dependent induction of apoptosis by the retinoid CD437 in p53-mutated keratinocytes. J Mol Med 2002; 80: 61-7.
48. Schadendorf D, Kern M, Artuc M, et al. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro and causes growth inhibition in xenografts in vivo. J Cell Biol 1996; 135: 1889-98.
49. Langdon SP, Rabiasz GJ, Ritchie AA, et al. Growth-inhibitory effects of the synthetic retinoid CD437 against ovarian carcinoma models in vitro and in vivo. Cancer Chemother Pharmacol 1998; 42: 429-32.
50. Ponzanelli I, Gianni M, Giavazzi R, et al. Isolation and characterization of an acute promyelocytic leukemia cell line selectively resistant to the novel antileukemic and apoptogenic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid. Blood 2000; 95: 2672-82.
51. Zhang Y, Dawson MI, Mohammad R, et al. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 2002; 100: 2917-25.
52. Ortiz MA, Lopez-Hernandez FJ, Bayon Y, Pfahl M, Piedrafita FJ. Retinoid-related molecules induce cytochrome c release and apoptosis through activation of c-Jun NH(2)-terminal kinase/p38 mitogen-activated protein kinases. Cancer Res 2001; 61: 8504-12.
53. Lovat PE, Ranalli M, Bernassola F, et al. Synergistic induction of apoptosis of neuroblastoma by fenretinide or CD437 in combination with chemotherapeutic drugs. Int J Cancer 2000; 88: 977-85.
54. Lovat PE, Ranalli M, Bernassola F, et al. Distinct properties of fenretinide and CD437 lead to synergistic responses with chemotherapeutic reagents. Med Pediatr Oncol 2000; 35: 663-8.
55. Kumar A, Soprano DR, Parekh HK. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res 2001; 61: 7552-5.
56. Bernard BA, Bernardon J-M, Deleiscluse C, et al. Identification of synthetic retinoids with selectivity for human nuclear retinoic receptor. Biochem Biophys Res Commun 1992; 186: 977-83.
57. Spanjaard RA, Ikeda M, Lee PJ, Charpentier B, Chin WW, Eberlein TJ. Specific activation of retinoic acid receptors (RARs) and retinoid X receptors reveals a unique role for RARgamma in induction of differentiation and apoptosis of S91 melanoma cells. J Biol Chem 1997; 272: 18990-9.
58. Meister B, Fink FM, Hittmair A, Marth C, Widschwendter M. Antiproliferative activity and apoptosis induced by retinoic acid receptor-gamma selectively binding retinoids in neuroblastoma. Anticancer Res 1998; 18: 1777-86.
59. Holmes WF, Dawson MI, Soprano RD, Soprano KJ. Induction of apoptosis in ovarian carcinoma cells by AHPÑCD437 is mediated by retinoic acid receptors. J Cell Physiol 2000; 183: 61-7.
60. Marchetti P, Zamzami P, Joseph B, Schraen-Maschke S, et al. The novel retinoid 6-[3-(1adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus. Cancer Res 1999; 59: 6257-66.
61. Zhao X, Demary K, Wong L, et al. Retinoic acid receptor-independent mechanism of apoptosis of melanoma cells by the retinoid CD437 (AHPN). Cell Death Differ 2001; 8: 878-86.
62. Dawson MI, Hobbs PD, Peterson VJ, et al. Apoptosis induction in cancer cells by a novel analog of 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid lacking retinoid transcriptional activity. Cancer Res 2001; 61: 4723-30.
63. Fontana JA, Dawson MI, Lied M, et al. Identification of a unique binding protein specific for a novel retinoid inducing cellular apoptosis. Int J Cancer 2000; 86: 474-9.
64. Fei P, Bernhard EJ, El-Deiry WS. Tissue-specific induction of p53 targets in vivo. Cancer Res 2002; 62: 7316-27.
65. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002; 2: 594-604.
66. Shao Z-M, Dawson MI, Li X-S, et al. P53 independent G1-G0 arrest and apoptosis induced by a novel retinoid in human breast cancer cells. Oncogene 1995; 11: 493-504.
67. Sun SY, Yue P, Wu GS, et al. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non-small cell lung carcinoma cells. Oncogene 1999; 18: 2357-65.
68. Adachi H, Preston G, Harvat B, Dawson MI, Jetten AM. Inhibition of cell proliferation and induction of apoptosis by the retinoid AHPN in human lung carcinoma cells. Am J Respir Cell Mol Biol 1998; 18: 323-33.
69. Li Y, Lin B, Agadir B, et al. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines. Mol Cell Biol 1998; 18: 4719-31.
70. Sun SY, Yue P, Wu GS, et al. Implication of p53 in growth arrest and apoptosis induced by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 1999; 59: 2829-33.
71. Rishi AK, Sun RJ, Gao Y, et al. Post-transcriptional regulation of the DNA damage-inducible gadd45 gene in human breast carcinoma cells exposed to a novel retinoid CD437. Nucleic Acids Res 1999; 27: 3111-9.
72. Sakaue M, Adachi H, Jetten AM. Post-transcriptional regulation of MyD118 and GADD45 in human lung carcinoma cells during 6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid-induced apoptosis. Mol Pharmacology 1999; 55: 668-76.
73. Fontana JA Sun RJ, Rishi AK, et al. Overexpression of bcl-2 or bcl-XL fails to inhibit apoptosis mediated by a novel retinoid. Oncol Res 1998; 10: 313-24.
74. Sun SY, Yue P, Hong WK, Lotan R. Augmentation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by the synthetic retinoid G-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) through up-regulation of trail receptors in human lung cancer cells. Cancer Res 2000; 60: 7149-55.
75. Holmes WF, Soprano DR, Soprano KJ. Elucidation of molecular events mediating induction of apoptosis by synthetic retinoids using a CD437-resistant ovarian carcinoma cell line. J Biol Chem 2002; 277: 45408-19.
76. Li H, Kolluri SK, Gu J, et al. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3. Science (Wash. DC) 2000; 289: 1159-64.
77. Marchetti P, Mortier L, Beauvillain V, Formstecher P. Are mitochondria targets of anticancer drugs responsible for apoptosis? Ann Biol Clin (Paris) 2002; 60: 391-403.
78. Ravagnan L, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J Cell Physiol 2002; 192: 131-7.
79. Hail N Jr, Youssef EM, Lotan R. Evidence supporting a role for mitochondrial respiration in apoptosis induction by the synthetic retinoid CD437. Cancer Res 2001; 61: 6698-702.
80. Halestrap AP, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimie 2002; 84: 153-66.
81. Hsu CK, Rishi AK, Li XS, et al. Bcl-X(L) expression and its downregulation by a novel retinoid in breast carcinoma cells. Exp Cell Res 1997; 232: 17-24.
82. Wan X, Duncan MD, Nass P, Harmon JW. Synthetic retinoid CD437 induces apoptosis of esophageal squamous HET-1A cells through the caspase-3-dependent pathway. Anticancer Res 2001; 21: 2657-63.
83. Sakaue M, Adachi H, Dawson M, Jetten AM. Induction of Egr-1 expression by the retinoid AHPN in human lung carcinoma cells is dependent on activated ERK1/2. Cell Death Differ 2001; 8: 411-24.
84. Srivastava RK TRAIL/Apo-2L: mechanisms and clinical applications in cancer. Neoplasia 2001; 3: 535-46.
85. Torres M. Mitogen-activated protein kinase pathways in redox signaling. Front Biosci 2003; 8: D369-91.
86. Hatai T, Matsuzawa A, Inoshita S, et al. Execution of apoptosis signal-regulating kinase 1 (ASK1)-induced apoptosis by the mitochondria-dependent caspase activation. J Biol Chem 2000; 275: 26576-81.
87. Zhuang S, Demirs JT, Kochevar IE. p38 mitogen-activated protein kinase mediates bid cleavage, mitochondrial dysfunction, and caspase-3 activation during apoptosis induced by single oxygen but not by hydrogen peroxide. J Biol Chem 2000; 275: 25939-48.
88. Assefa Z, Vantieghem A, Garmyn M, et al. p38 mitogen-activated protein kinase regulates a novel, caspase-independent pathway for the mitochondrial cytochrome c release in ultraviolet B radiation-induced apoptosis. J Biol Chem 2000; 275: 21416-21.
89. MacFarlane M, Cohen GM, Dickens M. JNK (c-Jun N-terminal kinase) and p38 activation in receptor-mediated and chemically-induced apoptosis of T-cells: differential requirements for caspase activation. Biochem J 2000; 348 Pt 1: 93-101.
90. Zhang Y, Huang Y, Rishi AK, et al. Activation of the p38 and JNK-SAPK mitogen-activated protein kinase pathways during apoptosis is mediated by a novel retinoid. Exp Cell Res 1999; 247: 233-40.
91. Muller M, Wilder S, Bannasch D, et al. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J Exp Med 1998; 188: 2033-45.
92. Wu GS, Burns TF, McDonald III ER, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17: 141-3.
93. Sheikh MS, Fornace AJ, Jr. Death and decoy receptors and p53-mediated apoptosis. Leukemia 2000; 14: 1509-13.
94. Guan B, Yue P, Clayman GL, Sun SY. Evidence that the death receptor DR4 is a DNA damage-inducible, p53-regulated gene. J Cell Physiol 2001; 188: 98-105.
95. Burns TF, El-Deiry WS. The p53 pathway and apoptosis. J Cell Physiol 1999; 181: 231-9.
96. Sun SY, Yue P, Lotan R. Implication of multiple mechanisms in apoptosis induced by the synthetic retinoid CD437 in human prostate carcinoma cells. Oncogene 2000; 19: 4513-22.
97. Cappello P, Novelli F, Forni G, Giovarelli M. Death receptor ligands in tumors. J Immunother 2002; 25: 1-15.
98. Sun SY, Yue P, Hong WK, Lotan R. Induction of Fas expression and augmentation of Fas ligand-mediated apoptosis by the synthetic retinoid CD437 in human lung cancer cells. Cancer Res 2000; 60: 6537-43.
99. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271: 12687-90.
100. Gazitt Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 1999; 13: 1817-24.
101. Adachi H, Adams A, Hughes FM, Zhang J, Cidlowski JA, Jetten AM. Induction of apoptosis by the novel retinoid AHPN in human T-cell lymphoma cells involves caspase-dependent and independent pathways. Cell Death Differ 1998; 5: 973-83.
102. Zhang Y, Beard RL, Chadraratna RAS, Kang JX. Evidence of lysosomal pathway for apoptosis induced by the synthetic retinoid CD437 in human leukemia cells. Cell Death Diff 2001; 8: 477-85.
103. Sawai H, Okazaki T, Yamamoto H, et al. Requirement of AP-1 for ceramide-induced apoptosis in human leukemia HL-60 cells. J Biol Chem 1995; 270: 27326-31.
104. Preston GA, Lyon TT, Yin Y, et al. Induction of apoptosis by c-Fos protein. Mol Cell Biol 1996; 16: 211-8.
105. Sun SY, Yue P, Chandraratna RA, Tesfaigzi Y, Hong WK, Lotan R. Dual mechanisms of action of the retinoid CD437: nuclear retinoic acid receptor-mediated suppression of squamous differentiation and receptor-independent apoptosis in UMSCC2B human head and neck squamous cell carcinoma cells. Mol Pharmacol 2000; 58: 508-14.
106. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Induction of apoptosis in human non-small cell lung carcinoma cells by the novel synthetic retinoid CD437. J Cell Physiol 1997; 173: 279-84.
107. Packham G, Cleveland J. c-Myc and apoptosis. Biochem Biophys Acta 1995; 1242: 11-28.
108. Packham G, Porter CW, Cleveland JL. c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 1996; 13: 461-9.
109. Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 1996; 382: 511-7.
110. Sun SY, Yue P, Shroot B, Hong WK, Lotan R. Implication of c-Myc in apoptosis induced by the retinoid CD437 in human lung carcinoma cells. Oncogene. 1999; 18: 3894-901.
111. Philips A, Lesage S, Gingras R, et al. Novel dimeric nur77 signaling mechanism in endocrine and lymphoid cells. Mol Cell Biol 1997; 17: 5946-51.
112. Liu ZG, Smith SW, McLaughlin KA, Schwartz LM, Osborne BA. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77. Nature 1994; 367: 281-4.
113. Woronicz JD, Cainan B, Ngo V, Winoto A. Requirement for the orphan steroid receptor nur77 in apoptosis of T-cell hybridomas. Nature 1994; 367: 277-80.
114. Williams GT, Lau LF. Activation of the inducible orphan receptor gene nur77 by serum growth factors: dissociation of immediate-early responses. Mol Cell Biol 1993; 13: 6124-36.
115. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999; 341: 233-49.
116. Zoratti M, Szabò I. The mitochondrial permeability transition. Biochim Biophys Acta 1995; 1241: 139-76.
117. Gu Z, Flemington C, Chittenden T, Zambetti GP. ei24, a p53 response gene involved in growth suppression and apoptosis. Mol Cell Biol 2000; 20: 233-41.
118. Farhana L, Dawson M, Rishi AK, et al. Cyclin B and E2F-1 expression in prostate carcinoma cells treated with the novel retinoid CD437 are regulated by the ubiquitin-mediated pathway. Cancer Res 2002; 62: 3842-9.
119. Zhang Y, Rishi AK, Dawson MI, et al. S-phase arrest and apoptosis in normal mammary epithelial cells by a novel retinoid. Cancer Res 2000; 60: 2025-32.
120. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998; 12: 2245-62.
121. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature 2001; 411: 342-8.
122. Trimarchi JM, Lees JA. Sibling rivalry in the E2F family. Nature Rev Mol Cell Biol 2002; 3: 1-20.
123. Nahle Z, Polakoff J, Davuluri RV, et al. Direct coupling of the cell cycle and cell death machinery by E2F. Nat Cell Biol 2002; 4: 859-64.
124. Appierto V, Cavadini E, Pergolizzi R, et al. Decrease in drug accumulation and in tumour aggressiveness marker expression in a fenretinide-induced resistant ovarian tumour cell line. Br J Cancer 2001; 84: 1528-34.
125. Garattini E, Gianni' M, Terao M. Correspondence re: A. Kumar et al., cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Cancer Res 2002; 62: 2192-3.
126. Sun SY, Kurie JM, Yue P, et al. Differential responses of normal, premalignant and malignant bronchial epithelial cells to receptor selective retinoids. Clin Cancer Res 1999; 5: 431-7.
127. Lu XP, Fanjul A, Picard N, Shroot B, Pfahl M. A selective retinoid with high activity against an androgen-resistant prostate cancer cell type. Int J Cancer 1999; 80: 272-8.
128. Arafa HM, Elmazar MM, Hamada FM, et al. Selective agonists of retinoic acid receptors: comparative toxicokinetics and embryonic exposure. Arch Toxicol 2000; 73: 547-56.
129. Chao W, Hobbs PD, Long L, et al. Effects of receptor class and subtype: selective retinoids and an apoptosis inducing retinoid on the adherent growth of the NIH: OVCAR-3 ovarian cancer cell line in culture. Cancer Lett 1997; 113: 1-7.
130. Zhang D, Holmes WF, Wu S, et al. Retinoids and ovarian cancer. J Cell Physiol 2000; 185: 1-20.
131. Wu S, Zhang D, Donigan A, et al. Effects of conformationally restricted synthetic retinoids on ovarian tumor cell growth. J Cell Biochem 1998; 68: 378-88.
132. Costa SL, Paillaud E, Fages C, et al. Effects of a novel synthetic retinoid on malignant glioma in vitro: inhibition of cell proliferation, induction of apoptosis and differentiation. Eur J Cancer 2001; 37: 520-30.
133. Sun SY, Kurie JM, Yue P, et al. Differential responses of normal, premalignant and malignant bronchial epithelial cells to receptor selective retinoids. Clin Cancer Res 1999; 5: 431-7.
134. Li XS, Rishi AK, Shao ZM, et al. Post-transcriptional regulation of p21 WAF1-CIP1 expression in human breast carcinoma cells. Cancer Res 1996; 56: 5055-62.
135. Liang JY, Fontana JA, Rao JN, et al. Synthetic retinoid CD437 induces S-phase arrest and apoptosis in human prostate cancer cells LNCaP and PC-3. Prostate 1999; 38: 228-36.
136. Oridate N, Higuchi M, Suzuki S, et al. Rapid induction of apoptosis in human C33A cervical carcinoma cells by the synthetic retinoid 6-[3-(1-adamantyl)hydroxyphenyl]-2-naphtalene carboxylic acid (CD437). Int J Cancer 1997; 70: 484-7.
137. Oridate N, Lotan D, Mitchell MF, et al. Inhibition of proliferation and induction of apoptosis in cervical carcinoma cells by retinoids: implications for chemoprevention. J Cell Biochem Suppl 1995; 23: 80-6.
138. Danielsson C, Torma H, Vahlquist A, et al. Positive and negative interaction of 1,25-dihydroxyvitamin D3 and the retinoid CD437 in the induction of human melanoma cell apoptosis. Int J Cancer 1999; 81: 467-70.
139. Hsu SL, Yin SC, Liu MC, et al. Involvement of cyclin-dependent kinase activities in CD437-induced apoptosis. Exp Cell Res 1999; 252: 332-41.
140. Jiang SY, Lin DY, Shyu RY, et al. The RARgamma selective agonist CD437 inhibits gastric cell growth through the mechanism of apoptosis. Cancer Lett 1999; 137: 217-25.